Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium adolescentis ATCC 15703
- Development stage
- Preclinical
- Lead developer
- Sir Run-Run Shaw Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Bifidobacterium adolescentis* ATCC 15703 is a specific strain of anaerobic, Gram-positive bacteria belonging to the genus *Bifidobacterium*. It is being investigated as a live biotherapeutic product (probiotic) for the treatment of inflammatory bowel disease (IBD), particularly ulcerative colitis. The strain exerts its therapeutic effects by reinforcing the intestinal epithelial barrier through the upregulation of tight junction proteins like occludin and mucin family members (MUC2, MUC3). Additionally, it modulates the host immune response by stimulating the differentiation of T-regulatory (Treg) and Th2 cells, which leads to an increase in anti-inflammatory cytokines (IL-10, IL-4, IL-5) and a decrease in pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). Research also indicates that this strain helps remodel the gut microbiota by inhibiting the overgrowth of potentially pathogenic genera such as *Akkermansia* and *Escherichia-Shigella*.
- Other names
- B. adolescentis ATCC 15703Bifidobacterium adolescentis strain ATCC 15703
02
Targets
MUC3A (Mucin-3A)OCLN (Occludin)
Beyond the preview
Go deeper on Bifidobacterium adolescentis ATCC 15703.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium adolescentis ATCC 15703.